BRCA1 and ovarian carcinoma: Improved mechanistic understanding and higher resolution laboratory identification of BRCA1/2 genetic variation subtypes and non-BRCA1/2 genetic aberrations contribute to the clinical care that breast and ovarian cancer patients receive.